Loading...

DTIL PRECISION BIOSCIENCES INC Expansion Plans 8-K Filing

PRCS

DTL

PRECISION BIOSCIENCES INC

(DTIL)

2024 8-K

Funding Announcement

Clinical Trial Update

Financial Results Announcement

Management Changes

Financial Statements

Clinical Trials

Elections of Directors

Financial Statements

Financial Results

Board Reclassification

Board Resignation

Financial Update

Financial Results

Financial Update

Management Changes

Convertible Note Maturity

Financial Results Announcement

Annual Meeting Approval

Financial Results Announcement

Private Placement

Termination of Agreement

Earnings Reports

Underwriting Agreement

Reverse Stock Split

Employment Agreements

Meeting Results

License Agreement with TG C...

Amendments to Bylaws

Financial Results Announcement

Amendment to Lease Agreement

Lease Agreement Extension

Management Changes

Asset Purchase Agreement

Financial Results Announcement

Program Updates and Clinica...

Annual Meeting of Stockholders

Earnings Reports

Financial Results and Confe...

No Exposure to Silicon Vall...

Financial Results Announcement

Departure of Chief Science ...

Earnings Update

External Links:

Precision BioSciences expects to report approximately $121 million in cash as of September 30, 2024, and has received clinical trial application clearance in Moldova for its lead candidate PBGENE-HBV for chronic hepatitis B treatment.

AI Assistant

PRECISION BIOSCIENCES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.